ESCMID-EUCIC 多重耐药革兰阴性菌携带者去定植临床指南
本指南由 ESCMID-EUCIC 制定,系统综述了针对多种多重耐药革兰阴性菌(MDR-GNB)携带者的去定植干预研究,并按菌种给出推荐。专家组不推荐对产超广谱β-内酰胺酶肠杆菌(3GCephRE)和碳青霉烯耐药肠杆菌(CRE)携带者常规去定植,其余多种耐药菌因证据不足无法给出推荐。
要点
- 不推荐对 3GCephRE 和 CRE 携带者常规去定植。
- AGRE、CoRGNB、CRAB、CRSM、FQRE、PDRGNB、XDRPA 证据不足,无法推荐或反对。
- 建议在免疫抑制 CRE 携带者中开展高质量前瞻研究并监测耐药。
核心结论
- 专家组不推荐对 3GCephRE 和 CRE 携带者常规去定植。
- 对 AGRE、CoRGNB、CRAB、CRSM、FQRE、PDRGNB 和 XDRPA 携带者,现有证据不足以推荐或反对任何去定植干预。
- 基于免疫抑制携带者中 CRE 感染风险升高的有限证据,建议设计高质量前瞻性临床研究评估该风险。
研究设计与样本
- 本指南为 ESCMID-EUCIC 制定的循证临床指南,基于对已发表去定植干预研究的系统综述。
- 目标菌包括 3GCephRE、CRE、AGRE、FQRE、XDRPA、CRAB、CRSM、CoRGNB 和 PDRGNB,推荐按菌种分组。
- 证据等级与推荐强度采用 GRADE 方法,最终推荐经多学科专家组名义组技术达成共识。
主要发现
- 每种目标 MDR-GNB 评估四类结局:微生物学结局(治疗结束时及特定随访时点的携带率与清除率)、临床结局(归因与全因死亡率、感染发生率及住院时长)、流行病学结局(获得率、传播与暴发)和不良事件(含耐药发生)。
- 粪菌移植被单独讨论。
- 指南未报告各菌种去定植干预的具体效应数值。
关键数值与推荐
- 不推荐对 3GCephRE 和 CRE 携带者常规去定植(推荐条款)。
- 对 AGRE、CoRGNB、CRAB、CRSM、FQRE、PDRGNB 和 XDRPA 携带者,证据不足,无法给出推荐或反对意见(推荐条款)。
- 建议在免疫抑制 CRE 携带者中开展高质量前瞻性临床研究,评估 CRE 感染风险(建议条款)。
- 上述试验应使用粪便培养和按 EUCAST 临床折点判读的药敏结果监测治疗期间去定植药物耐药的发生(建议条款)。
临床怎么用
- 临床不应常规对 3GCephRE 和 CRE 携带者实施去定植。
- 对多数其他 MDR-GNB 携带者,去定植决策应结合个体情况,并优先纳入研究场景。
- 免疫抑制 CRE 携带者应重点评估感染风险,相关研究需监测去定植药物耐药。
局限性
- 多数目标 MDR-GNB 的去定植证据不足,无法形成明确推荐。
- 指南未报告具体研究的样本量、效应值和统计显著性数据。
- 粪菌移植证据被单独讨论,未纳入本指南主要推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCOPE: The aim of these guidelines is to provide recommendations for decolonizing regimens targeting multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings. METHODS: These evidence-based guidelines were produced after a systematic review of published studies on decolonization interventions targeting the following MDR-GNB: third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE), aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), colistin-resistant Gram-negative organisms (CoRGNB), and pan-drug-resistant Gram-negative organisms (PDRGNB). The recommendations are grouped by MDR-GNB species. Faecal microbiota transplantation has been discussed separately. Four types of outcomes were evaluated for each target MDR-GNB:(a) microbiological outcomes (carriage and eradication rates) at treatment end and at specific post-treatment time-points; (b) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time-points and length of hospital stay; (c) epidemiological outcomes (acquisition incidence, transmission and outbreaks); and (d) adverse events of decolonization (including resistance development). The level of evidence for and strength of each recommendation were defined according to the GRADE approach. Consensus of a multidisciplinary expert panel was reached through a nominal-group technique for the final list of recommendations. RECOMMENDATIONS: The panel does not recommend routine decolonization of 3GCephRE and CRE carriers. Evidence is currently insufficient to provide recommendations for or against any intervention in patients colonized with AGRE, CoRGNB, CRAB, CRSM, FQRE, PDRGNB and XDRPA. On the basis of the limited evidence of increased risk of CRE infections in immunocompromised carriers, the panel suggests designing high-quality prospective clinical studies to assess the risk of CRE infections in immunocompromised patients. These trials should include monitoring of development of resistance to decolonizing agents during treatment using stool cultures and antimicrobial susceptibility results according to the EUCAST clinical breakpoints.
引用
- Tacconelli E, Mazzaferri F, de Smet AM, et al. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. Clin Microbiol Infect. 2019. PMID: 30708122. doi:10.1016/j.cmi.2019.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。